Needham Downgrades Hims & Hers Stock Amid Novo Nordisk Partnership Fallout
Hims & Hers Health (HIMS) shares plummeted 35% Monday after Novo Nordisk terminated their partnership, alleging illegal sales of Wegovy copycats. Needham analyst Ryan MacDonald downgraded HIMS to Hold, citing litigation risks and competitive disadvantages in the GLP-1 drug market.
Wall Street now views HIMS as exposed to regulatory scrutiny under FDA's 503A compounded drug provisions. The stock's removal from Needham's Conviction List reflects eroded confidence in its growth trajectory amid legal uncertainties.